Efficacy and safety of tabalumab, an anti-B-cellactivating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: Results from a phase III multicentre, randomised, double-blind study

Josef S. Smolen, Michael E. Weinblatt, Désirée Van Der Heijde, William F.C. Rigby, Ronald Van Vollenhoven, Clifton O. Bingham, Melissa Veenhuizen, Anne Gill, Fangyi Zhao, Wendy J. Komocsar, Pierre Yves Berclaz, Robert Ortmann, Chin Lee

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of tabalumab, an anti-B-cellactivating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: Results from a phase III multicentre, randomised, double-blind study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds